These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 14700633)

  • 1. GSK-3-selective inhibitors derived from Tyrian purple indirubins.
    Meijer L; Skaltsounis AL; Magiatis P; Polychronopoulos P; Knockaert M; Leost M; Ryan XP; Vonica CA; Brivanlou A; Dajani R; Crovace C; Tarricone C; Musacchio A; Roe SM; Pearl L; Greengard P
    Chem Biol; 2003 Dec; 10(12):1255-66. PubMed ID: 14700633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
    Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L
    J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
    Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
    J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.
    Vougogiannopoulou K; Ferandin Y; Bettayeb K; Myrianthopoulos V; Lozach O; Fan Y; Johnson CH; Magiatis P; Skaltsounis AL; Mikros E; Meijer L
    J Med Chem; 2008 Oct; 51(20):6421-31. PubMed ID: 18816110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis.
    Xingi E; Smirlis D; Myrianthopoulos V; Magiatis P; Grant KM; Meijer L; Mikros E; Skaltsounis AL; Soteriadou K
    Int J Parasitol; 2009 Oct; 39(12):1289-303. PubMed ID: 19445946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3.
    Efstathiou A; Gaboriaud-Kolar N; Smirlis D; Myrianthopoulos V; Vougogiannopoulou K; Alexandratos A; Kritsanida M; Mikros E; Soteriadou K; Skaltsounis AL
    Parasit Vectors; 2014 May; 7():234. PubMed ID: 24886176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Tyrian purple to kinase modulators: naturally halogenated indirubins and synthetic analogues.
    Vougogiannopoulou K; Skaltsounis AL
    Planta Med; 2012 Sep; 78(14):1515-28. PubMed ID: 22972384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death.
    Ribas J; Bettayeb K; Ferandin Y; Knockaert M; Garrofé-Ochoa X; Totzke F; Schächtele C; Mester J; Polychronopoulos P; Magiatis P; Skaltsounis AL; Boix J; Meijer L
    Oncogene; 2006 Oct; 25(47):6304-18. PubMed ID: 16702956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6.
    Wu ZL; Aryal P; Lozach O; Meijer L; Guengerich FP
    Chem Biodivers; 2005 Jan; 2(1):51-65. PubMed ID: 17191919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3.
    Atilla-Gokcumen GE; Williams DS; Bregman H; Pagano N; Meggers E
    Chembiochem; 2006 Sep; 7(9):1443-50. PubMed ID: 16858717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.
    Bertrand JA; Thieffine S; Vulpetti A; Cristiani C; Valsasina B; Knapp S; Kalisz HM; Flocco M
    J Mol Biol; 2003 Oct; 333(2):393-407. PubMed ID: 14529625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mediterranean purple indirubins: a source of GSK-3 inhibitors].
    Meijer L
    Med Sci (Paris); 2004 May; 20(5):516-8. PubMed ID: 15190467
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced bone loss.
    Wang FS; Ko JY; Weng LH; Yeh DW; Ke HJ; Wu SL
    Life Sci; 2009 Nov; 85(19-20):685-92. PubMed ID: 19782693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromo-substituted indirubins for inhibition of protein kinase-mediated signalling involved in inflammatory mediator release in human monocytes.
    Bachmann V; Schädel P; Westhoff J; Perić M; Schömberg F; Skaltsounis AL; Höppener S; Pantsar T; Fischer D; Vilotijević I; Werz O
    Bioorg Chem; 2024 Aug; 149():107470. PubMed ID: 38838619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.
    Pergola C; Gaboriaud-Kolar N; Jestädt N; König S; Kritsanida M; Schaible AM; Li H; Garscha U; Weinigel C; Barz D; Albring KF; Huber O; Skaltsounis AL; Werz O
    J Med Chem; 2014 May; 57(9):3715-23. PubMed ID: 24697244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation.
    Bax B; Carter PS; Lewis C; Guy AR; Bridges A; Tanner R; Pettman G; Mannix C; Culbert AA; Brown MJ; Smith DG; Reith AD
    Structure; 2001 Dec; 9(12):1143-52. PubMed ID: 11738041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The indirubin derivative 6-bromoindirubin-3'-glycerol-oxime ether (6BIGOE) potently modulates inflammatory cytokine and prostaglandin release from human monocytes through GSK-3 interference.
    Czapka A; König S; Pergola C; Grune C; Vougogiannopoulou K; Skaltsounis AL; Fischer D; Werz O
    Biochem Pharmacol; 2020 Oct; 180():114170. PubMed ID: 32710971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK versus GSK-3 inhibition: a purple haze no longer?
    Fischer PM
    Chem Biol; 2003 Dec; 10(12):1144-6. PubMed ID: 14700620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of benzo[e]isoindole-1,3-dione derivatives as selective GSK-3β inhibitors to activate Wnt/β-catenin pathway.
    Yue H; Lu F; Shen C; Quan JM
    Bioorg Chem; 2015 Aug; 61():21-7. PubMed ID: 26057861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
    Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
    J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.